Alnylam Pharmaceuticals, Inc
Head Quarters
3rd floor 300 Third Street USWebsite
http://www.alnylam.comIndustry
BiotechnologyEmployees
514Exchange
NASDAQAlnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Key statistics
| Margins | Stock |
|---|---|
| Revenue per Employee | $0.00 |
| Current Ratio | 6 |
| Gross Margin (%) | 0.00% |
| Net Margin (%) | -1.84% |
| Returns | Stock |
| Sales | $58.00M |
| Sales Growth (% qtr vs. yr ago) | 0.00% |
| Net Income | -$100.00M |
| NI Growth (% qtr vs. yr ago) | 0.00% |
| Price/Sales | 1,199.15 |
| EPS | -$4.00 |